WEAVE Trial

Condition: Stroke

Eligibility

Key Inclusion Criteria

  • Patients who have a Wingspan stent procedure attempted
  • Provides informed consent
  • Age 22–80 years 

Key Exclusion Criteria

  • Pregnant women
  • Children

Full Study Name

WEAVE Trial: Wingspan Stent System Post Market Surveillance Study (IRB no. 33256)

Summary

The purpose of this study is to fulfill a U.S. Food and Drug Administration requirement to collect information on the use of the Wingspan® Stent System with the Gateway® Percutaneous Transluminal Angioplasty Balloon Catheter, which has been approved as a Humanitarian Use Device. The device may allow a narrowed artery to become more open, thus permitting greater blood flow through the artery and to the brain.

Participants in this study will have had two or more strokes and have chosen to receive treatment with the Wingspan Stent System and Gateway PTA Balloon Catheter as part of their standard of care. The information collected will include the results of the procedure to better understand the benefits and risks of the Wingspan System.

Financial disclosure: Michael Alexander, MD, receives compensation from the company sponsoring this study. This includes consulting fees and fees for speaking engagements.

Phase

Phase IV


Principal Investigator

Michael Alexander, MD

Contact